Neisseria meningitidis compositions and methods thereof
US-9561269-B2 · Feb 7, 2017 · US
US9724402B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9724402-B2 |
| Application number | US-201615237005-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 15, 2016 |
| Priority date | Mar 9, 2012 |
| Publication date | Aug 8, 2017 |
| Grant date | Aug 8, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Opening claim text (preview).
What is claimed is: 1. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence set forth as SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 15. 2. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence set forth as SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is substituted, as compared to SEQ ID NO: 15. 3. The polypeptide according to claim 1 , wherein the polypeptide is immunogenic. 4. The polypeptide according to claim 1 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry. 5. The isolated polypeptide according to claim 1 , wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 68. 6. The isolated polypeptide according to claim 5 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 69. 7. The isolated polypeptide according to claim 1 wherein the amino acid sequence consists of the sequence set forth as SEQ ID NO: 64. 8. The isolated polypeptide according to claim 7 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 63. 9. An immunogenic composition comprising the polypeptide as in any of claims 1 , 3 , 4 , 5 , 6 , 7 , and 6 . 10. The composition according to claim 9 , further comprising an adjuvant.
Antibacterial agents · CPC title
Immunostimulants · CPC title
Neisseriaceae (F) · CPC title
Saponins; Quil A; QS21; ISCOMS · CPC title
Lipids, e.g. in lipopeptides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.